EPIMMUNE INC
10-Q, EX-27.1, 2000-11-14
PHARMACEUTICAL PREPARATIONS
Previous: EPIMMUNE INC, 10-Q, 2000-11-14
Next: INFRACORPS INC, 10QSB, 2000-11-14



<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM SEC FORM
10-Q FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2000 AND IS QUALIFIED IN ITS
ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                           1,137
<SECURITIES>                                     7,188
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                   474
<PP&E>                                           1,369
<DEPRECIATION>                                     370
<TOTAL-ASSETS>                                  13,186
<CURRENT-LIABILITIES>                            1,534
<BONDS>                                            404<F1>
                                0
                                         14
<COMMON>                                            73
<OTHER-SE>                                      11,072<F2>
<TOTAL-LIABILITY-AND-EQUITY>                    13,186
<SALES>                                              0
<TOTAL-REVENUES>                                 2,522
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                 4,406<F3>
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                  51
<INCOME-PRETAX>                                (3,673)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                            (3,673)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (3,673)
<EPS-BASIC>                                   (0.54)
<EPS-DILUTED>                                   (0.54)
<FN>
<F1>INCLUDES BONDS, MORTGAGES AND OTHER LONG-TERM DEBT, INCLUDING CAPITALIZED
LEASES.
<F2>INCLUDES ADDITIONAL PAID IN CAPITAL, OTHER ADDITIONAL CAPITAL AND RETAINED
EARNINGS, APPROPRIATED AND UNAPPROPRIATED (EXCLUDES UNREALIZED LOSS ON
SECURITIES)
<F3>PER CHIEF ACCOUNTANT AT SEC, THIS AMOUNT EXCLUDES SALES AND G&A EXPENSES,
INCLUDES COSTS AND EXPENSES APPLICABLE TO SALES AND REVENUES, AND TANGIBLE
COSTS OF GOODS SOLD.
</FN>


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission